Introduction
Dengue is the most prevalent mosquito-borne viral infection and a major public health problem in the world, with approximately 2.5 billion people living in dengue endemic areas worldwide, and 50 million dengue infections occurring annually. 1e3 The conventional classification of dengue illness as dengue fever (DF) or dengue hemorrhagic fever (DHF) put forward by the World health organization (WHO) in 1975 was based on the results of studies in pediatric patients conducted at the Children's Hospital, Bangkok, Thailand. 4 The diagnosis of DHF established in dengue infection required the fulfillment of all of the following criteria: fever, hemorrhagia, thrombocytopenia (<100 Â 10 9 cells/L) and clinical evidence of plasma leakage resulting from increased vascular permeability. 5 The severity of DHF was categorized as follows: Grade I Z fever accompanied by non-specific constitutional symptoms with the only hemorrhagic manifestation being a positive tourniquet test result; Grade II Z spontaneous bleeding is observed, in addition to the manifestations of Grade I; Grade III Z circulatory failure manifested by rapid and weak pulse and narrowing of pulse pressure or hypotension, with the presence of cold clammy skin; and Grade IV Z profound shock with undetectable blood pressure and pulse. Grades III and IV were categorized as dengue shock syndrome (DSS). 5 Over the past decades, dengue has geographically expanded and increasingly affected adult populations. 1e3,6e10 A wide variety of dengue clinical manifestations have continuously been unveiled, adding to the major dengue presentations that were initially conceived to be mainly confined to fever and hemorrhagia. 11e13 Of note, It has been increasingly reported that severe dengue might not fulfill the criteria of DHF/DSS, yet put affected patients at high risk for mortality. 14e19 Numerous reports on critically ill dengue affected patients who died of causes other than DHF/DSS have urged for a revision of the convention WHO dengue classification, so that it could elicit practical warning signs in a timely fashion and provide appropriate treatment guidelines for severe dengue.
11e13,20e24 For practical reasons, the latest WHO dengue classification scheme issued in 2009 stratified dengue-affected patients, based on the clinical manifestations, laboratory parameters and the clinical-service delivery, into severe dengue and non-severe dengue cases. 1 However, the usefulness of WHO dengue classification 2009 scheme has not yet been fully evaluated. 1 Taiwanese clinicians are particularly inexperienced with the WHO 2009 dengue classification and treatment guidelines as most of the large dengue epidemics in Taiwan occurred before 2009. 24, 25 The aim of this study was to evaluate the difference in clinical and laboratory features between patients who were separately classified based on the WHO classification 1997 and 2009 schemes, and the implications of these differences will be discussed.
Materials and methods

Patients and definitions
Patients with a diagnosis of acute dengue virus (DENV) infection admitted to Kaohsiung Chang Gung Memorial Hospital (KSCGMH), a 2700-bed medical facility serving as a primary and tertiary referral center in southern Taiwan, between 2008 and 2010 were included for retrospective analysis. The medical charts of the included patients were reviewed for retrieval of demographic, clinical, laboratory and imaging information. All included dengue cases were confirmed by at least one of the following criteria: (i) a positive reverse transcriptase-polymerase chain reaction (RT-PCR) result in acute-phase serum, (ii) a positive result for specific immunoglobulin M antibody in acute-phase serum, (iii) a fourfold increase in dengue-specific hemagglutination inhibition titer in convalescent serum as compared with that in acutee phase, and (iv) a dengue-specific nonstructural glycoprotein NS1 detected in acute-phase serum.
26e28 These diagnostic tests were performed by the Taiwan Center for Disease Control (CDC, Taiwan).
All included patients had their blood sampled for the assay of hemogram upon their arrival at KSCGMH. Additional blood chemistry and follow-up hemogram tests during hospital stay were carried out at the discretion of his or her physician as was clinically indicated. An organ impairment in the dengue-affected patient referred to any of the following clinical conditions: pulmonary edema, respiratory failure, severe gastrointestinal tract bleeding, severe hepatitis and rhabdomyolysis. 1 Severe hepatitis was defined as an elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1000 U/L [normal range (NR), ALT and AST, <40 U/L], 1 rhabdomyolysis are five or more times the upper limit of normal serum creatine kinase (NR, 20e130 U/L) and/or presence of myoglobin in the blood and/or urine, 29 and severe gastrointestinal bleeding as the passage of large amount of tarry or bloody stool coupled with hemodynamic instability and/or rapid decrease in hemoglobin level. 13 Plasma leakage referred to the presence of pleural effusion, ascites, and/or hemoconcentration. Hemoconcentration referred to >20% increase in hematocrit calculated as: (maximum hematocrit -minimum hematocrit) Â 100%/ minimum hematocrit. Table 1 . 1, 5 Briefly, the WHO 1997 scheme classified dengue disease into DF and DHF (Grades IÀIV) 5 ; the WHO 2009 scheme classified dengue disease into dengue without warning signs, dengue with warning signs (i.e., abdominal pain/ tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleed, lethargy, liver enlargement >2 cm, and increase in hematocrit concurrent with rapid decrease in platelet count), and severe dengue. 1 Furthermore, the 2009 WHO scheme categorized dengue-affected patients into: (i) Group A Z patients without warnings signs, (ii) Group B Z patients with ! one warning sign, patients with ! one coexisting conditions (i.e., pregnancy, infancy, old age, obesity, diabetes mellitus, renal failure, and chronic hemolytic diseases), and/or those with certain social circumstances (e.g., living alone or living far from a healthcare facility), and (iii) Group C Z patients with severe plasma leakage, severe bleeding, and/or organ impairment. 1 
Data collection and dengue classifications
The medical records of the included patients were reviewed. The demographics and evolutionary clinical, laboratory and imaging information of the included patients were retrieved and recorded in a case report form. These data were presented at a group discussion and the classified severity of dengue in individual patients based on WHO 1997 and 2009 classification schemes were the consensus of the participating infectious-disease physicians. 
Statistical analyses
Ethics statement
The study was conducted with a waiver of patient consent approved by the Institutional Review Board of KSCGMH (Document No.: 100-3061B). Tables 2 and 3 . The mean interval from dengue onset to hospital presentation was 3.7 AE 1.9 days. The most common underlying condition was hypertension (20%) and diabetes mellitus (11.3%). The three leading symptoms were fever (85.8%), myalgia (64.9%) and rashes (60%). As for warning signs, nausea/vomiting was found in 43 (29.1%) patients, mucosal bleeding (gum bleeding, hematuria and/or gastrointestinal bleeding) in 33 (22.3%), abdominal pain in 32 (21.6%), and drowsiness in one (0.7%). Platelet transfusion was given to 40 (27%) patients. Hemoconcentration was noted in 16 (10.8%) patients. Pleural effusion was found in 16 (15.1%) of the 106 patients with chest X-ray available, and ascites was detected in seven (8%) of the 87 patients with abdominal sonography available. Of the overall 64 DENV serotypes identified, DENV-3 accounting for 53.1%, followed by DENV-2 (28.1%), DENV-1 (17.2%) and DENV-4 (1.6%). All of the included patients survived.
Results
Characteristics of the overall included patients
Description of the included patients classified by the WHO 1997 scheme (Tables 2 and 3)
Of the 148 included patients, 119 [80.4%; median age, 45.7 years (range, 7e75)] were classified as suffering DF, and 29 [19.6%; median age, 53.7 years (range, 11e83)] as DHF. Seventy two (60.5%) of DF patients were hospitalized. Among the 119 DF patients, hemorrhage (gum bleeding, gastrointestinal bleeding and/or hematuria) was found in 27 (22.7%), the median platelet count was 56.5 Â 10 9 cells/ L (range, 3.0e202 cells/L), the median peak hematocrit level was 42.8% (range, 31.5%e53.7%), platelet transfusion was given to 25 (21%) patients and rhabdomyolysis was found in one (0.8%).
Twenty seven (93.1%) of the 29 DHF (19 Grade I and 10 Grade II) patients were hospitalized. Among the 29 DHF patients, severe gastrointestinal bleeding and rhabdomyolysis each was found in two patients (each 6.9%), the median platelet count was 42.8 Â 10 9 cells/L (range, 2.0e91), and the median peak hematocrit level was 44.7% (range, 27.7e58.2). and platelet transfusion was given to 15 (51.7%) patients. Fourteen DHF patients with RT-PCR data available, and DENV-3 was found to be the etiologic virus in seven (50%) of them.
Description of the included patients classified by the WHO 2009 scheme (Tables 2 and 3 Among the 64 patients [28 (43.7%) of the patients were hospitalized] in Group A, the three most common symptoms/sign were fever (81.3%), rashes (57.8%) and myalgia (54.7%), the median platelet count was 91.5 Â 10 9 cells/L (range, 3 to 202), and the median peak hematocrit level was 42.3% (range, 35.4e53.4); platelet transfusion was given to six (9.4%) patients.
Among the 77 [64 (83.1%) of the patients were hospitalized] patients in Group B, the three leading symptoms were fever (88.3%), myalgia (72.7%) and bone pain (57.1%); gastrointestinal bleeding developed in 12 (15.6%), the median platelet count was 35 Â 10 9 cells/L (range, 2e186), and the median peak hematocrit level was 43.6% (range, 34.5e58.2); platelet transfusion was given to 30 (39%) patients.
All the seven patients in Group C were admitted to hospital, and the three leading symptoms were fever (100%), bone pain, and myalgia (each 71.4%). The median platelet count was 21 Â 10 9 cells/L (range, 6e38), and the median peak hematocrit level was 43.4% (range, 27.7e53.7); platelet transfusion was given to four (57%) patients. The detailed demographics, clinical and laboratory features of the patients in Group C are summarized in Table 4 . Of the seven patients allocated in Group C, six (85.7%) patients were classified as suffering DHF Grade II (Patients 1, 2 and 4e7), and one as DF (Patient 3). Rhabdomyolysis was found in three patients (Patients 3, 6 and 7); severe hepatitis (Patients 1 and 6), severe gastrointestinal bleeding (Patients 2 and 6), and respiratory distress (Patients 4 and 5) each were found in two patients. Of the two patients experienced respiratory distress, pulmonary edema was noted in Patient 5, and persistent drowsiness with respiratory failure that necessitated mechanical ventilatory support was found in Patient 4. Ventilator associated pneumonia subsequently developed in Patient 4, and meropenem was thereby intravenously administrated. Of the three (Patients 3, 6, and 7) patients complicated with rhabdomyolysis, concurrent severe hepatitis and severe gastrointestinal bleeding were found in Patient 6. Of note, all of the three patients with rhabdomyolysis presenting with myalgia and weakness of both lower limbs. Tea-colored urine was overt in Patient 3; however, no evidence of plasma leakage was detected by chest radiography and frequent measurement of his hematocrit. DENV-3 was detected in three (75%) of the four patients in Group C with RT-PCR data available.
Clinical, laboratory and imaging features between dengue classified by WHO 2009 scheme and DF (Tables 2 and 3) Group A vs. DF Patients in Group A were significantly younger (36.1 AE 17.9 years vs. 43.8 AE 18.8 years; p Z 0.007); had lower prevalence of diabetes mellitus (0 vs. 7.9%; p Z 0.028), lower frequencies of abdominal pain (0 vs.18.5 %; p < 0.001), gum bleeding (0 vs. 8.5%; p Z 0.015), and gastrointestinal bleeding (0 vs. 8.4%; p Z 0.016); lower hospital admission rate (43.7 vs. 60.2%; p Z 0.043), and higher platelet count (median, 91.5 Â 10 9 cells/L vs. 56.5 Â 10 9 cells/L; p Z 0.024). Group C vs. DHF Patients in Group C were had significantly higher incidence of rhabdomyolysis (42.8% vs. 6.9%; p Z 0.040).
Cross tabulation of dengue Group A/B/C and DF/ DHF (Table 5 By contrast, 100% of the patients allocated in Group A in the current series were categorized as DF, and approximately 30% of Group B and 86% of Group C were categorized as DHF. These data suggest that when stratified by WHO dengue classification 2009 scheme, dengue patients classified in Group A should be treated on outpatient basis, and escalating proportions of dengue patients categorized from Group B to Group C need admission for close observation and/or intervention as necessary. Of note, the hospitalization rates in this series were found to be 60.5% in DF patients, 93.1% in DHF patients, and 43.7%, 83.1%, and 100% in patients in Group A, Group B, and Group C, respectively. In consistent with previous report, 31 our data suggest that the WHO 2009 scheme better discriminate different levels of clinical severity among dengue-affected patients.
In comparison to its 1997 version, the WHO dengue classification 2009 scheme were also reported to have a higher sensitivity and specificity in identifying dengue cases that clinically progress requiring intensive care. 31 As dengue features clinically dynamic change over time, 13, 31 when being treated on outpatient basis for whatever reasons, the dengue-affected patient categorized in Group A or Group B and the family should be notified to pay careful attention to the potential emergence of any newly developing warning sign and/or exacerbation of the preexisting warning sign(s) that necessitates hospitalization.
In addition to addressing what happens in dengue patients surrounding the plasma leakage and bleeding as the WHO 1997 version did, the WHO 2009 scheme include the warning signs as monitor targets and severe organ impairment as part of the criteria in severe dengue, 1 comprehensively depicting what happens in reality. For instance, clinical manifestations of dengue patients categorized in Group C in this series (Table 4) were obviously much better detailed by the WHO 2009 scheme than by its previous version. This is not surprising as the WHO 2009 version was written to provide practical guidance to deal with dengue, which often occurs as a large-scale epidemic in areas where medical resources are deficient. On top of that, the WHO 2009 scheme takes into account other factors such as coexisting conditions (e.g., pregnancy, infancy, old age, diabetes mellitus, and renal failure) and social circumstances (e.g., living alone and/or far from a hospital) when it comes to consideration for dengue patient hospitalization for close observation. 1 During the 3-year-study period, there were more than 3000 cases of symptomatic dengue cases notified in Taiwan. 32 DENV-1 was circulating in 2008, while DENV-3 was the predominant serotype between 2009 and 2010 and DENV-2 was sporadically found in 2010. 32 DENV-2 was reported to be more clinically virulent and associated with severe manifestations in some series. 33, 34 Of note, Narvaez et al. 31 reported that DENV-2 was significantly associated with DHF/DSS, suggesting that the WHO dengue 2009 scheme was no longer specific in identifying severe dengue due to DENV-2. The association of DENV-2 and clinical severity was not found in our series. Rather, DENV-3 was found to be the most common serotype detected in patients with DHF and in those categorized in Group C. The higher linking between DENV-3 and DHF/severe dengue in our series partly resulted from the fact that DENV-3 was the dominant serotype in circulation during the study period.
There are some limitations in our study. First, the study was conducted at a single medical center, and the dengue severity of patients may therefore be biased by referral pattern. Second, the small sub-grouped case numbers make the statistical power quite small. Third, being a retrospective study, missing data for some included patients were unavoidable.
In conclusion, data from this study show that the WHO 2009 scheme is effective in identifying severe dengue cases. Heterogeneity in severity suggested careful severity discrimination in patients classified in Group B by clinicians is needed. Our data suggests that it is safe to treat dengueaffected patients classified in Group A on outpatient basis.
